Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. Exploring efficiencies from eTMF with Cancer Research UK
  2. FDA accelerated review denial is a blow to Spectrum’s poziotinib
  3. New drugs and therapeutic options help the immune system fight cancer
  4. Roche’s Tecentriq threatens BMS’ Opdivo in small cell lung cancer market
  5. The challenges of using stem cells in neurology

Latest Content

Partnership presentation

Uniquid advantages of SOMAI PRO include identification of new mechanisms of action of drugs (biological activity defined by Molecular Field Maps, which were not described before and non-structural analogues identification reliable patent protection.

January’s top news stories

A Phase I clinical trial of monoclonal antibody (mAb) CIS43LS against malaria started the enrolment of healthy adults at the NIH Clinical Center in Bethesda, Maryland, US, and Acceleron Pharma reported that the Phase II PULSAR study of sotatercept achieved its primary and major secondary endpoints for the treatment of pulmonary arterial hypertension (PAH). Clinicaltrialsarena.com wraps up key headlines from January 2020.

Ethical GmbH upgrades eAdjudication®

Ethical GmbH upgrades the study designer functionality available with the eAdjudication® software platform to allow customers to independently create and configure new studies in their company dedicated workspace.

Latest News

Close
Close
Close

Go Top